FDA approves Astellas' gastric cancer therapy-March 2024-www.financetom.com

FDA approves Astellas' gastric cancer therapy

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

FDA approves Astellas' gastric cancer therapy

Oct 18, 2024 9:39 AM

Oct 18 (Reuters) - The U.S. Food and Drug Administration

approved Astellas' gastric cancer therapy, the health

regulator's website showed on Friday.

Previous page： Global smartphone market shrinks for eighth quarter in a row: Report Next page： Microsoft moves closer to completing $69 bn Activision takeover after court rebuffs regulators

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Global smartphone market shrinks for eighth quarter in a row: Report

Jul 18, 2023

Smartphone volumes fell 8% in the second quarter of 2023. Samsung remained the leader with a 22 percent market share. Apple held the second spot, achieving its highest-ever Q2 market share. Xiaomi, the third-largest brand, faced challenges in its key markets of China and India.

Microsoft moves closer to completing $69 bn Activision takeover after court rebuffs regulators

Jul 14, 2023

In a brief ruling, a three-judge panel on the 9th U.S. Circuit Court of Appeals concluded there were no grounds for issuing an order that would have prevented Microsoft from completing its nearly 18-month-old deal to take over the maker of popular video games such as Call of Duty.

US FTC asks court to halt Microsoft's acquisition of Activision

Jul 14, 2023

The FTC had said it was seeking a preliminary injunction to temporarily stop the deal until an internal FTC judge could assess it. But Corley applied the standard needed to permanently stop the deal instead, which the agency argued was inappropriate.

Mastek buys US-based BizAnalytica in boost for generative AI, global cloud capabilities

Jul 19, 2023

Shares of Mastek Ltd ended at Rs 2,177.00, up by Rs 24.15, or 1.12 percent on the BSE.